Lupin Digital Health (LDH) unveiled its study findings at the India Live 2023 symposium in Chennai.
The study results show the efficacy of digital therapeutics (DTx) among patients with Acute Coronary Syndrome (ACS) and post-percutaneous coronary interventions.
Lyfe, a digital therapeutics evidence-based platform significantly reduces the risk of a heart attack and improves the quality of life for patients with cardiac problems.
The year-long study aimed to evaluate the efficacy of Lyfe on cardiovascular events, rehospitalization, medication adherence, vital sign monitoring, and lifestyle changes among cardiac patients. During the 90-day interim analysis, the study participants demonstrated significant improvements, with 90 percent following the recommended medication, diet, and exercise regimen. 83.3 percent of patients maintained their vital signs within the normal range, and no rehospitalizations occurred during the first 30 days of enrolment.
The study results emphasize the crucial role that digital therapeutics programs can have in improving patients’ heart health. These results showcase a promising future for remote patient care in cardiology.
In a recent development, Lupin has also announced that it has received approval from the U.S. FDA for its Abbreviated New Drug Application for Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, a generic equivalent of Rexulti® Tablets of Otsuka Pharmaceutical Company Ltd. This product would be manufactured at Lupin’s Pithampur facility in India.